SSG
ADPT icon

Summit Securities Group’s Adaptive Biotechnologies ADPT Stock Holding History

Summit Securities Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,300
Closed -$11K – 904
2022
Q2 		$11K Buy
+1,300
New +$11.4K ﹤0.01% 826

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Summit Securities Group's ADPT Position: Q1 2024 in Review

Summit Securities Group sold out of Adaptive Biotechnologies (ADPT) in Q1 2024, closing a stake of 20,491 shares — an estimated $100K sold.

Summit Securities Group first reported a position in ADPT in Q4 2023 and held it in 1 quarter. The position peaked at $100K in Q4 2023. 190 funds tracked by Wall St. Rank hold ADPT as of Q1 2024.

  • Summit Securities Group reported no remaining Adaptive Biotechnologies position as of Q1 2024 after selling out during the quarter.
  • Summit Securities Group sold 20,491 Adaptive Biotechnologies shares in Q1 2024, an estimated $100K.
  • Summit Securities Group first reported a position in Adaptive Biotechnologies in Q4 2023 and held it in 1 quarter.
  • Summit Securities Group's Adaptive Biotechnologies position peaked at $100K in Q4 2023.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2024.

Based on Summit Securities Group's 13F filing for Q1 2024, filed 13 May 2024.